Literature DB >> 29943995

Asymmetric Construction of 3-Azabicyclo[3.1.0]hexane Skeleton with Five Contiguous Stereogenic Centers by Cu-Catalyzed 1,3-Dipolar Cycloaddition of Trisubstituted Cyclopropenes.

Hua Deng1, Wu-Lin Yang1, Fei Tian1, Wenjun Tang1,2, Wei-Ping Deng1,2.   

Abstract

A highly diastereo- and enantioselective desymmetrization of prochiral cyclopropenes via a Cu(CH3CN)4BF4/Ph-Phosferrox complex catalyzed 1,3-dipolar cycloaddition of azomethine ylides was described. A variety of complex 3-azabicyclo[3.1.0]hexane derivatives bearing five contiguous stereogenic centers and two all-carbon quaternary stereogenic centers were directly synthesized as a single isomer in excellent yields (up to 99%) and enantioselectivities (97 → 99% ee). Notably, various functional groups (CO2R, CN, CONMe2, and Ph) of cyclopropenes were found to be well-tolerated in this transformation. The cycloadduct was conveniently converted to a biologically important GABA derivative via LiAlH4 reduction and subsequent hydrolysis.

Entities:  

Year:  2018        PMID: 29943995     DOI: 10.1021/acs.orglett.8b01686

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  3 in total

1.  Further Developments and Applications of Oxazoline-Containing Ligands in Asymmetric Catalysis.

Authors:  Robert Connon; Brendan Roche; Balaji V Rokade; Patrick J Guiry
Journal:  Chem Rev       Date:  2021-05-21       Impact factor: 60.622

2.  Synthesis of bis-spirocyclic derivatives of 3-azabicyclo[3.1.0]hexane via cyclopropene cycloadditions to the stable azomethine ylide derived from Ruhemann's purple.

Authors:  Alexander S Filatov; Olesya V Khoroshilova; Anna G Larina; Vitali M Boitsov; Alexander V Stepakov
Journal:  Beilstein J Org Chem       Date:  2022-06-29       Impact factor: 2.544

3.  Synthesis of bicyclo[3.1.0]hexanes by (3 + 2) annulation of cyclopropenes with aminocyclopropanes.

Authors:  Bastian Muriel; Alec Gagnebin; Jerome Waser
Journal:  Chem Sci       Date:  2019-10-08       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.